



**BRAWN**



047C7

CIN NO.: L74899DL1985PLC022468

To,

Date: 10<sup>th</sup> November, 2017

Department of Corporate Services  
Bombay Stock Exchange Limited  
25<sup>th</sup> Floor, P.J Towers,  
Dalal Street,  
Mumbai- 400001

Dear Sir/ Madam,

**Sub: Outcome of 6<sup>th</sup> Board Meeting for Financial Year 2017-18**

**Ref: BSE Scrip Code: 530207**

We would like to inform you that the 6<sup>th</sup> / 2017-18 meeting of the Board of Directors held today i.e, **Friday, 10<sup>th</sup> of November, 2017**, commenced at **02:00 P.M** and concluded at **05:10 P.M**, at the Registered Office of the Company situated at 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002, inter alia considered the following:

1. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, approved the unaudited Quarterly/ half yearly Financial Results for quarter/ half year ended on 30<sup>th</sup> September, 2017. A copy of the aforesaid results is enclosed herewith as **Annexure- I**.
2. Limited Review Report on Un- audited Quarterly/ half yearly Financial Results for quarter/ half year ended on 30<sup>th</sup> September, 2017 obtained from Statutory Auditor has also been taken on record and a copy of the same is enclosed herewith as **Annexure- II**.
3. Approved the appointment of Mr. Subhash Chander as an Additional Director (Non- Executive, Independent) of the Company to hold office upto the date of ensuing general meeting of the Company.
4. Approved the appointment of Mrs. Kanta Takkar as an Additional Director (Non- Executive, Independent) of the Company to hold office upto the date of ensuing general meeting of

**BRAWN BIOTECH LTD.**

(Formerly Known as Brawn Pharmaceuticals Ltd.)

For Brawn Biotech Limited

*[Signature]*


... for better life

Regd. Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 0124-4666152, 4222462,  
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

Export Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 011-23275208 Fax : 011-23275208

Corporate Office : Plot No. - 30, Sector - 33 , Near Hero Honda Factory, Gurugram (Haryana) 122001 , Tel.: 0124-4666152, 4222462  
Email: solution@brawnbiotech.com

Works : 13, Industrial Area, N.I.T., Faridabad -121001 (Haryana) Tel.: +91 - 8010416849/48



# BRAWN



093F2

CIN NO.: L74899DL1985PLC022468

the Company.

5. With the permission of Chair, Board has approved Reconstitution of Committees.

Kindly acknowledge the receipt and take on record.

Thanking You,

Yours truly,

For and On behalf of

Brawn Biotech Limited

For Brawn Biotech Limited

Mamta Surkali Company Secretary

Company Secretary

## BRAWN BIOTECH LTD.

(Formerly Known as Brawn Pharmaceuticals Ltd.)

...for better life

**Regd. Office :** 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 0124-4666152, 4222462,  
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

**Export Office :** 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 011-23275208 Fax : 011-23275208

**Corporate Office :** Plot No. - 30, Sector - 33 , Near Hero Honda Factory, Gurugram (Haryana) 122001 , Tel.: 0124-4666152, 4222462  
Email: solution@brawnbiotech.com

**Works :** 13, Industrial Area, N.I.T., Faridabad -121001 (Haryana) Tel.: +91 - 8010416849/48



**BRAWN**

**BRAWN BIOTECH LIMITED**  
CIN:L74899DL1985PLC022468  
REGD. OFFICE: 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002

STATEMENT OF UN- AUDITED FINANCIAL RESULTS FOR THE QUARTER/HALF-YEAR ENDED ON 30TH SEPTEMBER, 2017							Rs. In Lac
Sr. No.	Particulars	Quarter Ended			Half- year ended		Year ended
		30.09.2017	30.06.2017	30.09.2016	30.09.2017	30.09.2016	31.03.2017
		Un-audited	Un-audited	Un- audited	Un- audited	Un- audited	Audited
1	Revenue from operations						
	Revenue from operations	1,159.52	1,094.34	1,280.83	2,253.85	2,729.79	5,960.58
	Other Income	18.04	15.94	21.57	33.98	48.43	94.10
	<b>Total Revenue</b>	<b>1,177.55</b>	<b>1,110.28</b>	<b>1,302.40</b>	<b>2,287.83</b>	<b>2,778.22</b>	<b>6,054.68</b>
2	Expenses						
a	Cost of material consumed	-	-	-	-	-	-
b	Purchase of stock-in-trade	988.81	997.46	1,119.95	1,986.27	2,386.45	5,206.74
c	Change in inventories of finished goods, work in progress and stock in trade	10.01	(2.59)	15.54	7.42	22.59	12.32
d	Employee Benefit expenses	56.43	51.59	49.48	108.02	94.13	198.14
e	Depreciation and amortisation expenses	0.80	0.78	0.82	1.58	1.52	3.11
f	Finance Cost	0.55	0.52	0.78	1.07	1.08	6.55
g	Other expenses	36.22	37.02	97.20	73.24	216.75	514.24
	<b>Total Expenses</b>	<b>1,092.81</b>	<b>1,084.78</b>	<b>1,283.77</b>	<b>2,177.59</b>	<b>2,722.52</b>	<b>5,941.09</b>
3	Profit from Operation before Other Income, exceptional and extra-ordinary items (1-2)	84.74	25.50	18.63	110.24	55.70	113.59
4	Other Income	-	-	-	-	0.55	4.44
5	Profit from ordinary activities before exceptional items (3-4)	84.74	25.50	18.63	110.24	56.25	118.03
6	Exceptional Items	-	-	57.60	-	57.60	57.60
7	Profit from ordinary activities before tax (5-6)	84.74	25.50	76.23	110.24	113.85	175.63
8	Tax Expenses	27.96	8.72	11.89	36.68	24.10	36.33
9	Profit (Loss) for the period from continuing operations (7-8)	56.78	16.78	64.34	73.56	89.75	139.29
10	Profit/(loss) from discontinuing operations	-	-	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-	-	-
12	Profit/(loss) from Discontinuing operations (after tax) (10-11)	-	-	-	-	-	-
13	Profit (Loss) for the period (9+12)	56.78	16.78	64.34	73.56	89.75	139.29
14	Other Comprehensive Income	0.33	(0.13)	-	0.20	-	(0.05)
	<b>Total Comprehensive Income</b>	<b>57.11</b>	<b>16.65</b>	<b>64.34</b>	<b>73.76</b>	<b>89.75</b>	<b>139.24</b>
15	Details of equity share capital						
	Paid-up equity share capital	300.03	300.03	300.03	300.03	300.03	300.03
	Face value of equity share capital						
16	Reserve excluding Revaluation Reserve	411.41	354.30	342.33	411.41	342.33	337.65
17	Earnings per share						
i	Basic earnings per share	1.90	0.55	2.14	2.46	2.99	4.64
ii	Diluted earnings per share	1.90	0.55	2.14	2.46	2.99	4.64

**NOTES :-**

- Results for the quarter ended 30th September, 2017 were reviewed by the Audit committee and then approved by the Board of Directors at their meeting held on 10th November, 2017.
- The above results have been prepared in compliance with the recognition and measurement principles of the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as amended by the Companies (Indian Accounting Standards) (Amendment rules), 2016 prescribed under Section 133 of the companies Act, 2013 and other recognized accounting practices and policies to the extent applicable. Beginning 1<sup>st</sup> April, 2017, the Company has for the first time adopted Ind AS with Transition date of 1<sup>st</sup> April, 2016.
- The Statutory Auditors carried out the "Limited Review" of the results for the quarter ended 30<sup>th</sup> September, 2017. The Ind AS Compliant financial results pertaining to the corresponding quarter ended 30<sup>th</sup> September, 2016, have not been subjected to limited review or audit. However, the management has exercised necessary due diligence to ensure that the financial results provided a true and fair view of its affairs.
- The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.
- The above Standalone Unaudited Financial Results for the quarter ended 30.09.2017 are available on company's website [www.brawnbiotech.com](http://www.brawnbiotech.com) and BSE website [www.bseindia.com](http://www.bseindia.com).
- Reconciliation between financial results as per previous Indian GAAP and Ind AS for the quarter ended 30th September, 2016.

		(Rs. In Lac)		
Sr. No.	Description	Sub Notes	Half year ended 30th September, 2016	Quarter ended 30th September, 2016
	Net Profit as per previous Indian GAAP		89.75	64.34
1	Fair Valuation adjustments for financial assets	(i)	-	-
2	Actuarial loss on employee defined benefits plan recognised in OCI	(ii)	-	-
3	Deferred Tax impact on Ind AS adjustments	(iii)	-	-
	<b>Net Profit as per Ind AS</b>		<b>89.75</b>	<b>64.34</b>

**BRAWN BIOTECH LTD.**  
(Formerly Known as Brawn Pharmaceuticals Ltd.)

Regd. Office : C-64, LAJPAT NAGAR-1, NEW DELHI-110024 TEL.: 91-11-29815331 Email : [legals@brawnbiotech.com](mailto:legals@brawnbiotech.com) Website : [www.brawnbiotech.com](http://www.brawnbiotech.com)


Export Office : OLD DELHI STOCK EXCHANGE BUILDING 4/4B, ASAF ALI ROAD, NEW DELHI-110002 (INDIA) TEL.: 011-32911528, 32911529 FAX: 011-23275208  
Email: [export@brawnbiotech.com](mailto:export@brawnbiotech.com)

Corporate Office : Plot No. - 30, Sector - 33 Near Hero Honda Factory, Gurgaon (Haryana) 122001 TEL.: 0124-4666152, 4222462, E-mail: [admin@brawnbiotech.com](mailto:admin@brawnbiotech.com)

Works : 13, NEW INDUSTRIAL TOWNSHIP, FARIDABAD-121001 (HR) TEL.: 0129-3290659 / 3290738 E-mail : [plant\\_fbd@brawnbiotech.com](mailto:plant_fbd@brawnbiotech.com)

*...for better life*





# BRAWN

**Sub Notes:**

- (i) Under Indian GAAP, current Investments were measured at lower of cost and net realisable value. Under Ind AS, financial assets other than those valued at amortised cost are subsequently measured at fair value.
- (ii) Under Indian GAAP, re-measurement gain/loss on defined benefits plans is charged to the Statement of Profit and Loss. Under Ind AS, such re-measurement gain/loss is reported as an item that will not be reclassified to profit or loss under the Statement of other Comprehensive Income (OCI).
- (iii) Under India GAAP, deferred taxes are recognised using Income statement approach i.e. reflecting the tax effects of timing differences between accounting income and taxable income for the period. The impact of transition adjustments together with Ind AS mandate of using balance sheet approach (against income approach under Indian GAAP) for computation of deferred tax has resulted in consequential impact to Statement of Profit and Loss.
- 7 Previous year / period figures have been regrouped / rearranged, wherever necessary to make them comparable with the current period figures.

For and on behalf of Board  
For Brawn Biotech Limited

Brij Raj Gupta  
Managing Director  
DIN NO. 00974969  
Date : 10-11-2017  
Place: Delhi



## BRAWN BIOTECH LTD.

(Formerly Known as Brawn Pharmaceuticals Ltd.)

*...for better life*

Regd. Office : C-64, LAJPAT NAGAR-1, NEW DELHI-110024 TEL.: 91-11-29815331 Email : legal@brawnlab.com Website : www.brawnlab.com

Export Office : OLD DELHI STOCK EXCHANGE BUILDING 4/4B, ASAF ALI ROAD, NEW DELHI-110002 (INDIA) TEL.: 011-32911528, 32911529 FAX: 011-23275208  
Email: export@brawnlab.com

Corporate Office : Plot No. - 30, Sector - 33 Near Hero Honda Factory, Gurgaon (Haryana) 122001 TEL.: 0124-4666152, 4222462, E-mail: admin@brawnlab.com

Works : 13, NEW INDUSTRIAL TOWNSHIP, FARIDABAD-121001 (HR) TEL.: 0129-3290659 / 3290738 E-mail : plant\_fbd@brawnlab.com

**BRAWN**

BRAWN BIOTECH LIMITED

CIN:L74899DL1985PLC022468

Regd Office: 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002

Statement of Assets and Liabilities As on 30TH SEPTEMBER 2017		
Particulars	Standalone	
	30.09.2017 Un-audited Rupees in Lakhs	31.03.2017 Audited Rupees in Lakhs
<b>EQUITY AND LIABILITIES</b>		
<b>Shareholders' funds</b>		
(a) Share capital	300.03	300.03
(b) Reserves and surplus	411.41	337.65
(c) Money received against share warrants	-	-
<b>Sub Total Shareholder's Fund</b>	<b>711.44</b>	<b>637.68</b>
<b>Share application money pending allotment</b>		
<b>Non-current liabilities</b>		
(a) Long-term borrowings	-	-
(b) Deferred tax liabilities (Net)	-	-
(c) Other Long term liabilities	20.50	-
(d) Long-term provisions	11.59	9.90
<b>Sub Total Non Current Liabilities</b>	<b>32.09</b>	<b>9.90</b>
<b>Current liabilities</b>		
(a) Short-term borrowings	-	-
(b) Trade payables	470.74	681.92
(c) Other current liabilities	115.76	189.52
(d) Short-term provisions	37.44	184.03
<b>Sub Total Current Liabilities</b>	<b>623.95</b>	<b>1,055.48</b>
<b>Total Equity and Liabilities</b>	<b>1,367.49</b>	<b>1,703.06</b>
<b>ASSETS</b>		
<b>Non-current assets</b>		
(a) Fixed assets		
(i) Tangible assets	23.94	25.16
(ii) Intangible assets	-	-
(iii) Capital work-in-progress	-	-
(iv) Intangible assets under development	-	-
(b) Non-current investments	-	-
(c) Deferred tax assets (net)	5.20	4.72
(d) Long-term loans and advances	-	10.60
(e) Other non-current assets	-	-
<b>Sub Total Non Current Assets</b>	<b>29.13</b>	<b>40.47</b>
<b>Current assets</b>		
(a) Current investments	-	-
(b) Inventories	29.80	37.22
(c) Trade receivables	1,135.55	1,302.35
(d) Cash and cash equivalents	50.47	199.93
(e) Short-term loans and advances	18.29	123.08
(f) Other current assets	104.25	-
<b>Sub Total Current Assets</b>	<b>1338.36</b>	<b>1662.58</b>
<b>Total Assets</b>	<b>1367.49</b>	<b>1703.06</b>

For and on behalf of Board

For Brawn Biotech Limited

Brij Raj Gupta  
Managing Director  
DIN NO. 00974969  
Place : New Delhi  
Date : 10-11-2017

**BRAWN BIOTECH LTD.**

(Formerly Known as Brawn Pharmaceuticals Ltd.)

*...for better life*


Regd. Office : C-64, LAJPAT NAGAR-1, NEW DELHI-110024 TEL.: 91-11-29815331 Email : legal@brawnlabs.com Website : www.brawnlabs.com

Export Office : OLD DELHI STOCK EXCHANGE BUILDING 4/4B, ASAF ALI ROAD, NEW DELHI-110002 (INDIA) TEL.: 011-32911528, 32911529 FAX: 011-23275208  
Email: export@brawnlabs.com

Corporate Office : Plot No. - 30, Sector - 33 Near Hero Honda Factory, Gurgaon (Haryana) 122001 TEL.: 0124-4666152, 4222462, E-mail: admin@brawnlabs.com

Works : 13, NEW INDUSTRIAL TOWNSHIP, FARIDABAD-121001 (HR) TEL.: 0129-3290659 / 3290738 E-mail : plant\_fbd@brawnlabs.com



**BRAWN**

CIN NO.: L74899DL1985PLC022468

**BRAWN BIOTECH LIMITED**

CIN:L74899DL1985PLC022468

REGD. OFFICE: 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002

Extract of Standalone unaudited Financial Results for the quarter/half-year ended 30th September 2017

(Rs. In Lakhs)

Sr. No	Particulars	Standalone		
		Quarter ended 30.09.2017	Half year ended 30.09.2017	Quarter ended 30.09.2016
		Un-audited	Un-audited	Un-audited
1	Total income from operation	1,177.55	2,287.83	1,302.40
2	Net Profit/(Loss) from ordinary activities after tax	56.78	73.56	64.34
3	Net Profit/(Loss) for the period after tax (after extraordinary items)	56.78	73.56	64.34
4	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income]	57.11	73.76	64.34
5	Equity Share Capital	300.03	300.03	300.03
6	Reserve (excluding Revaluation Reserves as shown in the balance sheet of previous year)	411.41	411.41	342.33
7	Earning per share (before extraordinary items)(not annualised): (of rs. 10 each)			
	(a) Basic (Rs.)	1.90	2.46	2.14
	(b) Diluted (Rs.)	1.90	2.46	2.14
8	Earning per share (after extraordinary items)(not annualised): (of rs. 10 each)			
	(a) Basic (Rs.)	1.90	2.46	2.14
	(b) Diluted (Rs.)	1.90	2.46	2.14

**Notes:**

- The above is an extract of the detailed format of Quarterly financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015, read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016. The full format of the Quarterly financial results are available on the Stock Exchange website (www.bseindia.com) and on the company's website (www.brawnbiotech.com).
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 10-11-2017.
- The Financials has been prepared in accordance with Companies (Indian Accounting Standards) Rules 2015 (Ins-AS) to the extent applicable. The Company has for the first time adopted IND-AS beginning 01st April 2017 with transition date of 01st April, 2016.
- The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.
- Previous year/period figures have been regrouped/rearranged, wherever necessary to make them comparable with the current period figures.

For and on behalf of Board  
For Brawn Biotech LimitedBrij Raj Gupta  
Managing Director  
DIN NO. 00974969Place: Delhi  
Date: 10-11-2017**BRAWN BIOTECH LTD.**

(Formerly Known as Brawn Pharmaceuticals Ltd.)

...for better life

Regd. Office : C-64, LAJPAT NAGAR-1, NEW DELHI-110024 TEL.: 91-11-29815331 Email : legal@brawnlabs.com Website : www.brawnlabs.com

Export Office : OLD DELHI STOCK EXCHANGE BUILDING 4/4B, ASAF ALI ROAD, NEW DELHI-110002 (INDIA) TEL.: 011-32911528, 32911529 FAX: 011-23275208 Email: export@brawnlabs.com

Corporate Office : Plot No. - 30, Sector - 33 Near Hero Honda Factory, Gurgaon (Haryana) 122001 TEL.: 0124-4666152, 4222462, E-mail: admin@brawnlabs.com

Works : 13, NEW INDUSTRIAL TOWNSHIP, FARIDABAD-121001 (HR) TEL.: 0129-3290659 / 3290738 E-mail : plant\_fbd@brawnlabs.com



**Independent Auditor's Report on Quarterly/ half- yearly Standalone Financial Results of  
BRAWN BIOTECH LIMITED pursuant to Regulation 33 of the SEBI (Listing Obligations and  
Disclosure Requirements) Regulations, 2015**

To,  
The Board of Directors of  
Brawn Biotech Limited


We have reviewed the accompanying statement of Unaudited Financial Results of Brawn Biotech Limited (the "Company") for the quarter/ half- year ended on 30<sup>th</sup> September, 2017, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial results based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards i.e., Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Rajiv Udai & Associates  
Chartered Accountants

FRN: 18764N

  
Rajeev Jain

(Partner)

Membership No. 99767

Place: Delhi

Date: 10.11.2017

